RxDoctor Payments Data

Kelli Hall, MD

Dermatology · Baton Rouge, LANPI 1194041152

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $21,975 of the $31,317 with a category attached, or 70.2%. Pfizer accounts for 96.1% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $19,141 and has fallen 97.7% since, to $440 in 2025.

$31,317in general payments, 2019–2025

Across 63 payments — averaging $497.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$30K
  • Galderma Laboratories, L.p.$273
  • LEO Pharma Inc.$253
  • E.r. Squibb & Sons, L.L.C.$252
  • Organon$120
  • Johnson & Johnson$116
  • plus $203 from 7 others

What the payments were for

  • Consulting fees$6,25020%
  • Speaking & faculty fees$21,97570%
  • Travel & lodging$1,0153%
  • Food & beverage$1,9476%
  • Education$1300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,317 in reported general payments places this provider in the 85th percentile of 189 dermatology providers in Louisiana.

See all dermatology providers in Louisiana

Medicare billing

Part B allowed, 2024
$30,970
Medicare patients
190
Services billed
772

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab21$178,181
TremfyaGuselkumab12$160,998
Dupixent PenDupilumab22$78,786
OtezlaApremilast16$75,601
Dupixent SyringeDupilumab13$49,699
Betamethasone Dipropionate76$6,158
Clobetasol Propionate99$4,959
Mometasone Furoate168$3,481
Tacrolimus34$3,141
Tretinoin61$2,756
Doxepin Hcl16$2,514
Ketoconazole154$2,471
Dapsone14$2,357
Triamcinolone Acetonide179$1,884
Mycophenolate Mofetil19$1,589

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$116$160,99812 claims
AmgenOtezla$15$75,60116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 189 dermatology providers in Louisiana.

Other dermatology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →